DekaBank Deutsche Girozentrale Raises Stock Position in IQVIA Holdings Inc. $IQV

DekaBank Deutsche Girozentrale grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 198,648 shares of the medical research company’s stock after acquiring an additional 7,929 shares during the period. DekaBank Deutsche Girozentrale’s holdings in IQVIA were worth $31,225,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Everpar Advisors LLC raised its stake in shares of IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares during the period. Private Trust Co. NA raised its stake in shares of IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 67 shares during the period. Ballentine Partners LLC raised its stake in shares of IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance grew its holdings in IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 72 shares in the last quarter. Finally, Nemes Rush Group LLC grew its holdings in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $218.04 on Thursday. The firm has a market cap of $37.07 billion, a P/E ratio of 31.55, a P/E/G ratio of 2.40 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $231.34. The firm has a fifty day moving average of $193.27 and a two-hundred day moving average of $170.28.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $2.64 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IQV. Robert W. Baird raised their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Cowen reaffirmed a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays raised their price target on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Finally, Truist Financial raised their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.